• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Does Early GDM Screening in Obese Women Reduce Negative Pregnancy Outcomes?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Harper et al. (AJOG, 2020) investigated whether early screening for GDM improves perinatal outcomes in obese women

METHODS:

  • Randomized controlled trial (RCT)
  • Participants
    • Obese women (BMI ≥30 kg/m2)
    • Exclusion criteria: Pre-existing diabetes | Major medical illness | Bariatric surgery | Prior cesarean delivery
  • Exposures
    • Early screening at 14 to 20 weeks
    • Routine screening at 24 to 48 weeks
  • Study design
    • 50-g, 1-hour glucose challenge test
    • Followed by 100-g, 3-hour glucose tolerance test if screen ≥135 mg/dL
  • GDM diagnosed using Carpenter−Coustan criteria
    • If screen negative at 14 to 20 weeks, rescreened at 24 to 28 weeks
  • Primary outcome
    • Composite: Macrosomia (>4000 g) | Primary cesarean delivery | Hypertensive disease of pregnancy | Shoulder dystocia | Neonatal hyperbilirubinemia | Neonatal hypoglycemia within 48 hours following delivery
  • Sample size calculation
    • 58 women with gestational diabetes per group
    • 80% power with a 2-sided α of 0.05 to detect a 50% relative reduction in the incidence of the primary outcome
    • Sample size was reduced during interim analysis due to increased GDM baseline compared to original assumption (950 new total)

RESULTS:

  • 922 women were randomized with full outcomes
    • Early screening: 49.8% (459 women)
    • Routing screening: 50.2% (463 women)
    • Baseline characteristics similar between groups
  • Early screening group
    • GDM diagnosis: 15.0% (95% CI, 11.9 to 18.6%; 69 women)
      • <20 weeks: 6.3% (95% CI, 4.3 to 8.9%)
      • >24 weeks: 8.7% (95% CI, 6.3−11.7%)
  • Routine screening group
    • GDM diagnosis: 12.1% (95% CI 9.3 to 15.4%; 56 women)
  • Early screening did not reduce the incidence of the primary outcome (P=0.07)
    • Early screening: 56.9%
    • Routine screening: 50.8%
    • Relative risk 1.12 (95% CI, 0.99 to 1.26)

CONCLUSION:

  • Early screening for gestational diabetes in obese women did not reduce the composite of perinatal adverse outcomes compared to routine screening
  • Authors acknowledge that the study was powered to identify a large difference and smaller differences may not have been detected
  • ACOG recommends screening women with BMI ≥25 kg/m2 and additional risk factors (see ‘Related ObG Entry’ for summary of ACOG GDM guidelines) and the authors suggest that future studies should focus on this cohort

Learn More – Primary Sources:

Early gestational diabetes screening in obese women: a randomized controlled trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Updated ACOG Guidance on Gestational Diabetes
Practical obstetrics info for your women's healthcare practice
Screening for Gestational Diabetes: The ‘2 Step’ Approach
Does Metabolic Syndrome Contribute to a Longer Time to Pregnancy and Infertility, Independent of Obesity?
Does Ultrasound Early in Pregnancy Improve Fetal Cardiac Visualization in the Setting of Obesity?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site